SPARTAN has compiled a list of presentations and sessions worth seeing if you are interested in ankylosing spondylitis, spondyloarthritis and related disorders.
"The US has nearly 4.5% of the world’s population but accounts for more than 40% of global drug spending" reports JAMA Internal Medicine. US drug prices are nearly double those of Australia, Canada, and the United Kingdom, and the US spends twice as much on retail and nonretail drugs per capita as Switzerland, the country with the next highest spending.
ACR 2020 (aka ACR Convergence) is just around the corner, with the opening ceremonies and lecture starting Thursday, November 5th; followed by the full meeting beginning the next morning, Friday November 6th.
Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com
An open-label extension of the ASSET trial (abatacept in diffuse cutaneous systemic sclerosis) showed continued safety with significant improvements in the modified Rodnan Skin Score (mRSS) at 12 months, suggesting abatacept (ABA) may benefit early systemic sclerosis (SSc).
While there have been several promising new agents for systemic sclerosis, many have failed - with all noting the difficulties in appropriate outcomes and endpoints for clinical trials. With this in mind, the FDA was interested in hearing patients’ perspectives on systemic sclerosis and new drug development, and held a virtual meeting on 10/13/20.
The DISCOVER‐2 trial has shown that guselkumab, an interleukin‐23p19 was shown to be safe and effective in biologic‐naïve psoriatic arthritis (PsA) patients in a one year study.
JAMA Internal Medicine has published a review showing that most currently approved therapies for fibromyalgia (FM) do not have high-quality evidence to support their use; with some reducing pain or improving quality of life (QOL) in the short term, but overall effect size is not impressive.
Vedolizumab (Entyvio) was superior to infliximab (Remicade) for treating immune-mediated diarrhea and colitis (IMDC), a researcher reported.
In a retrospective study of patients with cancer, treatment with vedolizumab led to a 13% IMDC recurrence rate versus 28% with infliximab, according to Yinghong Wang, MD, PhD, of the MD Anderson Cancer Center in Houston.
A full read review of immune-mediated necrotizing myopathy is portrayed as a distinct subtype of inflammatory myopathies first described in 2004.
A new short‐term follow‐up study has shown no significant difference in outcomes and quality measures in patients with RA who were managed by telemedicine (compared to usual in-person care).
Yesterday the Food and Drug Administration's (FDA) "Vaccines and Related Biological Products Advisory Committee" convened a panel of experts to assess the development of vaccines for COVID-19 infection.
Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.
Bergman and colleagues have studied a large cohort of US rheumatologists and found that nearly half meet at least one criterion defining "burnout" among physicians.
The FDA has approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.
